Open an account

Intelligent Bio Solutions

INBS · NASDAQ

$1.67+$0.14 (+9.15%)TodayMarket closed ·
Prev close $1.53

About INBS

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. The company is headquartered in New York City, New York and currently employs 16 full-time employees. The company went IPO on 2020-12-23. The Company’s active product is the Intelligent Fingerprinting Platform, which consists of a portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its Intelligent Fingerprinting Drug Screening System (the IFP System) is a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The IFP System comprises a single-use tamper-evident drug screening cartridge for sample collection and the Intelligent Fingerprinting DSR-Plus portable analysis unit onto which ten fingerprint sweat samples are collected in under a minute before the portable analysis unit provides an on-screen result in under ten minutes.

Employees
54
Headquarters
New York City, New York
Listed
Dec 23, 2020
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
ibs.inc

INBS key statistics

Market cap
5.54M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
54.17K
Volume
38.78K
Open price
$1.49
High today
$1.75
Low today
$1.48
52 Week high
$24.90
52 Week low
$1.35

Intelligent Bio Solutions (INBS) at a glance

As of Oct 20, 2026, Intelligent Bio Solutions (INBS) shares are priced at $1.67, giving the company a market cap of 5.54M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.48 and $1.75. The current price is 12.8% above the day's low and 4.6% below its high.

Volume so far is 38.78K shares, below the average of 54.17K shares a day.

Over the past year Intelligent Bio Solutions has ranged from $1.35 to $24.90, and now sits 1% of the way up that range.

Intelligent Bio Solutions met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q4 FY26 it reported -$0.90 per share against an estimate of -$1.61.

INBS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 41.2% on average.

  1. Q2 FY23: reported -$55.20 per share against an estimate of -$269.28
  2. Q3 FY23: reported -$243.60 per share against an estimate of -$253.37
  3. Q4 FY23: reported -$229.20 per share against an estimate of -$182.38
  4. Q2 FY24: reported -$20.70 per share against an estimate of -$33.05
  5. Q3 FY24: reported -$14.30 per share against an estimate of -$8.87
  6. Q4 FY24: reported -$13.40 per share against an estimate of -$5.20
  7. Q1 FY25: reported -$7.00 per share against an estimate of -$5.41
  8. Q4 FY26: reported -$0.90 per share against an estimate of -$1.61

INBS news

  • Vandana Singh

    Intelligent Bio Submits Comprehensive Clinical Data to Enter US Drug Screening Market

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Henry Khederian

    Intelligent Bio Solutions Shares Surge Monday: What's Driving the Action?

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Monday's Intraday Session

Similar companies

Companies in the same industry as Intelligent Bio Solutions

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.